Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
August 14th, 2007
Novavax, Inc. (NASDAQ:NVAX) announced that it has begun vaccinating healthy volunteers in the first human clinical trial of its virus-like particle ("VLP") based pandemic influenza vaccine. The Phase I/IIa randomized, placebo-controlled clinical trial will evaluate the safety and immunogenicity of different doses of the H5N1 clade 2 VLP influenza vaccine in up to 230 healthy adults. The goals of the study are to demonstrate safety and to select a dose for evaluation in a Phase IIb immunogenicity study. The first subject was enrolled at Healthcare Discoveries in San Antonio, Texas, one of two U.S. clinical sites participating in the study. Novavax is developing vaccines...
Source: Virus Weekly (2007-08-14)
|
